Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/15
41.11 AUD   +1.38%
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
39.52 38.53 38.97 40.55 41.11 Last
114962 199088 88720 173756 103138 Volume
-2.95% -2.51% +1.14% +4.05% +1.38% Change
Estimated financial data (e)
Sales 2022 64,6 M 47,8 M 47,8 M
Net income 2022 30,9 M 22,8 M 22,8 M
Net cash position 2022 108 M 79,7 M 79,7 M
P/E ratio 2022 67,4x
Yield 2022 0,11%
Sales 2023 92,3 M 68,3 M 68,3 M
Net income 2023 42,3 M 31,3 M 31,3 M
Net cash position 2023 135 M 100 M 100 M
P/E ratio 2023 49,0x
Yield 2023 0,14%
Capitalization 2 031 M 1 508 M 1 502 M
EV / Sales 2022 29,8x
EV / Sales 2023 20,5x
Nbr of Employees -
Free-Float 79,2%
More Financials
Company
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the... 
More about the company
Ratings of Clinuvel Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CLINUVEL PHARMACEUTICALS LIMITED
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
10/05CLINUVEL PHARMACEUTICALS : Secures Clearances for Phase Two Study of DNA Repair Drug
MT
10/04CLINUVEL PHARMACEUTICALS : Progresses DNA Repair Program
PU
10/04Clinuvel Pharmaceuticals Limited Receives the Necessary Regulatory and Ethics Committee..
CI
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
09/02CLINUVEL PHARMACEUTICALS LIMITED : Ex-dividend day for final dividend
FA
08/26CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
08/26CLINUVEL PHARMACEUTICALS' : Net Profit Jumps 64% on Higher Drug Demand
MT
08/25CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
08/25CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
08/25CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
More news
News in other languages on CLINUVEL PHARMACEUTICALS LIMITED
10/05Clinuvel Pharmaceuticals obtient les autorisations pour l'étude de phase deux du médica..
08/27MÄRKTE ASIEN/Zurückhaltung vor Jackson Hole - PBoC stützt Schanghai
08/26Le bénéfice net de Clinuvel Pharmaceuticals bondit de 64 % en raison de la hausse de la..
2019ORIGINAL-RESEARCH : Clinuvel Pharmaceuticals Ltd (von Sphene Capital GmbH): Buy
2019HEISSE AKTIENTIPPS : Lust oder Frust?
More news
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 41,11 AUD
Average target price 33,92 AUD
Spread / Average Target -17,5%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED84.18%1 508
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.14.84%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336